1. Academic Validation
  2. A negative allosteric modulator demonstrates biased antagonism of the follicle stimulating hormone receptor

A negative allosteric modulator demonstrates biased antagonism of the follicle stimulating hormone receptor

  • Mol Cell Endocrinol. 2011 Feb 20;333(2):143-50. doi: 10.1016/j.mce.2010.12.023.
James A Dias 1 Béatrice Bonnet Barbara A Weaver Julie Watts Kerri Kluetzman Richard M Thomas Sonia Poli Vincent Mutel Brice Campo
Affiliations

Affiliation

  • 1 Wadsworth Center, David Axelrod Institute for Public Health, New York State Department of Health, Albany, NY 12208, United States. JDias@uamail.albany.edu
Abstract

High quality gamete production in males and females requires the pituitary gonadotropin follicle stimulating hormone (FSH). In this report a novel chemical class of small molecule inhibitors of FSH Receptor (FSHR) is described. ADX61623, a negative allosteric modulator (NAM), increased the affinity of interaction between (125)I-hFSH and human FSHR (hFSHR) five fold. This form of FSHR occupied simultaneously by FSH and ADX61623 was inactive for cAMP and progesterone production in primary cultures of rat granulosa cells. In contrast, ADX61623 did not block estrogen production. This demonstrates for the first time, biased antagonism at the FSHR. To determine if ADX61623 blocked FSH induction of follicle development in vivo, a bioassay to measure follicular development and oocyte production in immature female rats was validated. ADX61623 was not completely effective in blocking FSH induced follicular development in vivo at doses up to 100mg/kg as oocyte production and ovarian weight gain were only moderately reduced. These data illustrate that FSHR couples to multiple signaling pathways in vivo. Suppression of one pool of FSHR uncouples Gαs and cAMP production, and decreases progesterone production. Occupancy of another pool of FSHR sensitizes granulosa cells to FSH induced estradiol production. Therefore, ADX61623 is a useful tool to investigate further the mechanism of the FSHR signaling dichotomy. This may lead to a greater understanding of the signaling infrastructure which enables estrogen biosynthesis and may prove useful in treating estrogen dependent disease.

Figures
Products